Currently, there is a lack of biomarkers which could be used to guide anti-angiogenic therapy in patients of non-small cell lung cancer. Martin Reck, MD, PhD, from the Lung Clinic Grosshansdorf, Grosshansdorf, Germany talks to us about the LUME BioNIS trial (NCT02671422), an exploratory study which aims to examine whether genetic markers could be used to predict overall survival in patients treated with nintedanib and docetaxel. Prof. Reck explains the difficulty in finding participants for such a trial, and encourages patients to take part. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.